Breakthroughs In Gene Editing Allow For The Creation Of Superior Preclinical Oncology Models
Gene editing is getting a lot of attention in the [...]
Gene editing is getting a lot of attention in the [...]
One of the most widely used methods of modeling human [...]
Around 85% of preclinical drugs entering clinical trials in oncology never make it past Phase 1 because they fail to demonstrate sufficient efficacy due to testing in unselected patient populations 1-3. Many of these failed agents are targeted therapies, meaning that they target specific oncogenic driver mutations. However, not all tumors harbor the same, or even similar, driving mutations – these targeted therapies are often found to be beneficial in very small patient populations which would not be captured in an unselected-patient trial design.
While advances in in-vitro platforms have allowed researchers to better visually monitor a variety of aspects of tumor biology, a significant limitation of 3D cultured models for patient therapeutic monitoring or “patient avatars” is the lack of important components, such as the influence of surrounding tissues and potential cell-to-cell interactions, when studying cancer progression, treatment responses and outcomes. Patient derived xenograft models or PDX models overcome these limitations and other research challenges and provide a platform that is believed to more closely mimic the patient tumor.
Pharmaceutical researchers and regulators are increasingly aware of the influence [...]
An increased understanding of human tumors has created a solid [...]
A relatively common autoimmune disease, Type 1 Diabetes (T1D) is [...]
A relatively common autoimmune disease, Type 1 Diabetes (T1D) is [...]
Cancer is responsible for approximately 8 million deaths worldwide, with [...]
Humanized rodent models have been used extensively for studying autoimmune [...]